# Antihistamine Drugs Market

> 항히스타민제 시장 조사 보고서 – 2032년까지 예측

- **Forecast Period:** 2025 - 2035
- **CAGR:** 8.6%
- **2024:** $ 0.17 Billion
- **2025:** $ 0.18 Billion
- **2035:** $ 0.42 Billion
- **Key Players:** Companies such as Johnson & Johnson (US), Pfizer Inc. (US), Bayer AG (DE), Sanofi (FR), GlaxoSmithKline(GB), Novartis AG (CH), Merck & Co., Inc. (US), AstraZeneca (GB), Teva Pharmaceutical Industries Ltd. (IL) are some of the major participants in the market.

**Report ID:** MRFR/Pharma/2913-HCR · **Pages:** 206 · **Author:** Satyendra Maurya & Rahul Gotadki · **Last Updated:** July 20, 2026

**URL:** https://www.marketresearchfuture.com/reports/antihistamine-drugs-market-4266

---

## Market Summary

## **Global Antihistamine Drugs Market Overview**

Antihistamine Drugs Market Size was valued at USD 0.16 Billion in 2023. The Antihistamine Drugs market industry is projected to grow from USD 0.17 Billion in 2024 to USD 0.34 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.60% during the forecast period (2024 - 2032).Raising awareness about allergy-related therapies and the rising rate of Allergic rhinitis are the key market drivers contributing to the market’s growth and expansion. 

Source: Secondary Research, Primary Research, _Market Research Future_ Database, and Analyst Review

Anti-allergic drugs called antihistamines are used to treat several allergies. Additionally, these drugs are used to treat anxiety, motion sickness, and insomnia. The market is expanding as a result of more research and development activity. This will present advantageous chances for the market for antihistamine medications to expand. Additionally, increased drug releases and approvals will expand the market. Additionally, growing investments in cutting-edge technologies and a spike in new markets will create more favorable conditions for the expansion of the antihistamine medicine market throughout the projection period.

The rising prevalence of allergic responses and allergies globally and expanding public awareness are the main driving factors for antihistamine drugs.

Additionally, throughout the projected period, the market expansion is anticipated to be fueled by changing lifestyles and the release of novel medication therapies for treating allergic illnesses. At the same time, factors such as the patent life of pharmaceuticals, the release of generic versions, and adverse effects from therapy are anticipated to hinder market expansion throughout the projection period. Antihistaminic drugs stop the production and synthesis of chemical histamine, the primary trigger of allergic reactions. Dizziness, dry mouth, and blurred vision are side effects of antihistaminic medications.

Histamine is crucial in developing localized allergic reactions by promoting vascular permeability, edema, inflammation, and smooth muscle contraction. The mechanism of action of antihistamines is the blockade of histamine type 1 (H1) receptors.

They are also employed in managing skin allergies, such as urticarial. Antihistamines are used in cases of persistent allergies or other recurring disorders and for seasonal allergies. Due to their fast alleviation and lack of adverse effects, they are favored as the first line of therapy for hay fever and other allergies. The market for antihistamine medications will also grow due to growing public and private activities to raise awareness about treating diverse allergic reactions. These elements are anticipated to fuel the growth of the global market for antihistamines.

However, since many of these medications are no longer under patent, they have drawn both small and massive generic competitors, leading to fierce price competition and a decline in the market's value.

## **Antihistamine Drugs Market Trends**

### **Growing awareness about therapies related to allergies is driving the market growth**

Market CAGR for antihistamine drugs is being driven by the rising awareness about therapies related to allergies. The growing incidence of allergic responses and allergies worldwide and increased public knowledge about managing various reactions to allergens are the primary drivers impacting this market. Allergies remedies are projected to become more popular due to changing lifestyles and innovative pharmacological solutions. There is a considerable demand for these medicines, and the number of people is growing. However, patent expiry, the launch of generic forms of drugs, and the treatment of adverse reactions will likely restrain market expansion throughout the projection period.

Allergic rhinitis has grown over the previous three decades, as reported by the American College of Allergy, Asthma, and Immunology—40% of the people in the United States and Europe to inhalant allergens.

Additionally, changes in lifestyle and the launch of innovative medication treatments for managing allergy illnesses are projected to drive market expansion throughout the forecast period. New product releases and FDA permission for over-the-counter switching of prescription-based nasal sprays are expected to provide attractive opportunities to major industry participants. Collaboration with regional and local players is expected to assist businesses in expanding their geographic reach and offering of goods.

Because nasal antihistamines are the most efficient and popular route of administration, the COVID-19 epidemic boosted sales. However, antihistamine sales were hindered to some amount by restricted international borders, supply delivery networks, stock shortages, and lockdown limitations. According to FMI estimates, the COVID-19 industry will rebound in the following years. This is because of the rise in the need for nose sprays and the number of people who rely on this treatment. These trends will continue in the face of healthcare changes, affecting the demand forecast.

For instance, According to WHO's White Book on Allergy 2011-2012, allergic rhinitis impacted 10%-30% of the population, whereas the average lifetime incidence of urticarial disease was above 20%. A high prevalence of allergies and a rise in incidences among youngsters are expected to increase antihistamine consumption throughout the predicted period. Therefore, it is anticipated that demand for Antihistamine Drugs will increase throughout the projection period due to the rising awareness about allergies-related therapies. Thus, driving the Antihistamine Drugs market revenue.

## **Antihistamine Drugs Market Segment Insights**

### **Antihistamine Drugs Type Insights**

The Antihistamine Drugs market segmentation, based on type, includes Sedating and Non-Sedating. The non-sedating category dominated the market, accounting for 51% of market revenue (USD 0.1 billion) in 2022 due to its increased preference by patients and easy availability.

**Figure 1: Antihistamine Drugs Market, by Type, 2022 & 2032 (USD Billion)** 

_Source: Secondary Research, Primary Research, _Market Research Future_ Database, and Analyst Review_

### **Antihistamine Drugs Route of Administration Insights**

The Antihistamine Drugs market segmentation, based on the route of administration, includes oral route, parenteral route, and rectal route. The oral route category generated the highest revenue of about 45% (USD 0.07 billion) in 2022 due to its increased benefits and ease of availability.

### **Antihistamine Drugs Indication Insights**

The Antihistamine Drugs market segmentation, based on Indication, includes Allergy, Urticaria, and Dermatitis. The allergy category dominated the market, accounting for 39% of the market share (USD 0.06 billion) in 2022. Category growth is driven by the growing elderly population and the advent of innovative medication regimens used to manage allergic diseases that will accelerate market expansion.

### **Antihistamine Drugs End User Insights**

The Antihistamine Drugs market segmentation, based on End Users, includes Hospitals, Clinics, and Pharmaceutical Companies. Hospitals dominated the market, accounting for 46% of market revenue (USD 0.07 billion) in 2022. Hospitals are in charge of giving medications that either cure or assist patients in maintaining their illnesses. As a result of their success in managing allergies affecting the nose and eyes, they have gained competence in prescribing antihistamines.

**News**

A recent study has discovered concrete proof that an over-the-counter antihistamine may repair the multiple sclerosis patient's destroyed protective nerve sheath. The discovery of a biomarker by researchers, which can be used to gauge a drug's efficacy, has led to the possibility of a brand-new treatment for the crippling condition. The protective myelin coating surrounding nerves is attacked by the body's immune system in the autoimmune condition multiple sclerosis (MS), resulting in irreparable damage and obstructing brain-body communication. The symptoms of demyelination, or the breakdown of myelin, can range in intensity from tingling and numbness to vision impairment and paralysis.

### **Antihistamine Drugs Regional Insights**

By region, the research provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American Antihistamine Drugs market will dominate this market, owing to the increased incidence of allergic rhinitis and the increasing need for evaluating and managing allergic illnesses.

Further, the major countries studied in the market report are the US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

**Figure 2: Antihistamine Drugs Market Share by Region 2022 (USD Billion)** 

_Source: Secondary Research, Primary Research, _Market Research Future_ Database, and Analyst Review_

Europe region’s Antihistamine Drugs market accounts for the second-highest market share. Per the European Academy of Allergies and Clinical Immunology (EAACI), allergies will impact over fifty percent of all Europeans in the next years, boosting the overall market. Further, the German Antihistamine Drugs market holds the largest market share, and the UK Antihistamine Drugs market is anticipated to grow and expand steadily in the European region during the projected timeframe.

The Asia-Pacific Antihistamine Drugs Market is expected to grow significantly during the projected timeframe. This is due to increased demand for pharmaceuticals for treating allergies and skin problems. Moreover, China’s Antihistamine Drugs market dominates the market share, and the Indian Antihistamine Drugs market is anticipated to grow rapidly in the Asia-Pacific region during the projected timeframe.

## **Antihistamine Drugs Key Market Players & Competitive Insights**

Leading market players invested heavily in research and development (R&D) to scale up their manufacturing units and product lines, which will help the Antihistamine Drugs market grow worldwide. Market participants are also undertaking various organic or inorganic strategic approaches to strengthen and expand their footprint, with important market developments including new product portfolios, contractual deals, mergers and acquisitions, capital expenditure, higher investments, and strategic alliances with other organizations. Businesses are also coming up with marketing strategies such as digital marketing, social media influencing, and content marketing to increase their scope of profit earnings.

The Antihistamine Drugs industry must offer cost-effective and sustainable options to survive in a dynamic market.

Manufacturing locally to minimize operational expenses and offer aftermarket services to customers is one of the key business strategies organizations use in the Antihistamine Drugs industry to benefit customers and capture untapped market share and revenue. The Antihistamine Drugs industry has recently offered significant advantages to the medicine and service industry. Moreover, more industry participants are utilizing and adopting cutting-edge technology has grown substantially.

Major players in the Antihistamine Drugs market, including Johnson & Johnson Consumer Inc. (U.S.), Sanofi (France), Bayer AG (Germany), Pfizer (U.S.), CVS pharmacy (U.S.), Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (U.S.), and Prestige Brands Holdings, Inc. (U.S.), are attempting to expand market share and demand by investing in research and development (R&D) operations to produce sustainable and affordable solutions.

Bayer AG is a German international pharma and biotech corporation, one of the world's leading pharma corporations. It was created in 1863 by chemical merchant Friedrich Bayer and dye firm owner Johann Friedrich Wescott. The company’s headquarters are in Leverkusen, Germany. It develops, manufactures, and distributes goods in medical treatment, dietary habits, and technologically advanced materials. Pharmaceuticals, Crop Science, Consumer Health, Animal Health, and Covestro are its business segments. The Pharmaceuticals division develops, manufactures, and markets prescription drugs for cardiac and women's medical care; specialty therapies in cancer, hematology, and ophthalmology; and medical imaging devices and contrast agents.

The FDA authorized Bayer AG's Astepro to treat periodic and chronic allergies for non-prescription usage beginning in June 2021 via a temporary to non-prescription transfer. This FDA clearance has given people access to a secure, efficient nostril antihistamine without needing a healthcare practitioner.

Glenmark Pharma is a prominent creative pharmaceutical firm dedicated to improving people's lives worldwide. Gracias Saldanha created it in 1977, and it has its headquarters in Mumbai, India. They aim to uncover novel opportunities and improve the well-being of patients worldwide by creating remedies for medical gaps. They have a robust pipeline of new compounds in various stages of discovery aimed at lung disease, cancer, and skincare. Glenmark Pharma is developing cutting-edge treatments for an emerging world. Glenmark has almost 6000 employees spread throughout 80 countries, including 12 production facilities.

Glenmark Pharma will introduce Ryaltris, a novel spray for the nose, in India in May 2021. Glenmark is an innovator in the pulmonary area, having been the first to launch labeled versions cheaply in India.

### **Key Companies in the Antihistamine Drugs market include**

- [Johnson & Johnson Consumer Inc.](https://www.jnj.com/) (U.S.)
- Sanofi (France)
- Bayer AG (Germany)
- Pfizer (U.S.)
- CVS pharmacy (U.S.)
- Merck Sharp & Dohme Corp.(U.S.)
- Prestige Brands Holdings, Inc. (U.S.)

## **Antihistamine Drugs Market Industry Developments**

- **Q2 2024: FDA Approves First Generic Version of Xyzal (levocetirizine dihydrochloride) Oral Solution** The FDA approved the first generic version of Xyzal (levocetirizine dihydrochloride) oral solution for the treatment of indoor and outdoor allergies, expanding access to a widely used second-generation antihistamine.
- **Q1 2024: Sanofi launches Allegra-D 24 Hour Allergy & Congestion in new extended-release formulation in the U.S.** Sanofi announced the launch of a new extended-release formulation of Allegra-D 24 Hour, providing all-day relief for allergy and nasal congestion symptoms, further strengthening its OTC antihistamine portfolio.
- **Q2 2024: GSK receives European Commission approval for over-the-counter sale of Clarinex (desloratadine) in select EU countries** GSK announced that the European Commission has approved the switch of Clarinex (desloratadine) from prescription to over-the-counter status in several European Union countries, increasing consumer access to the antihistamine.
- **Q3 2024: Pfizer completes acquisition of allergy drugmaker Allermi for $1.2 billion** Pfizer finalized its acquisition of Allermi, a specialty pharmaceutical company focused on innovative antihistamine nasal sprays, expanding Pfizer’s allergy treatment portfolio.
- **Q2 2024: Bayer opens new manufacturing facility for Claritin production in Germany** Bayer inaugurated a new state-of-the-art manufacturing facility in Leverkusen, Germany, dedicated to increasing production capacity for its leading antihistamine brand, Claritin.
- **Q1 2025: Novartis announces partnership with Alnylam to develop next-generation antihistamine therapies** Novartis and Alnylam Pharmaceuticals entered a strategic partnership to co-develop RNAi-based antihistamine drugs targeting severe allergic conditions, aiming to advance novel treatment options.
- **Q2 2025: Johnson & Johnson acquires rights to new pediatric antihistamine syrup from BioPharmX** Johnson & Johnson acquired exclusive global rights to a novel pediatric antihistamine syrup developed by BioPharmX, expanding its children’s allergy medication offerings.
- **Q1 2024: Takeda receives Japanese regulatory approval for Telfast ODT (orally disintegrating tablet) for allergic rhinitis** Takeda announced that Japan’s Ministry of Health, Labour and Welfare approved Telfast ODT, an orally disintegrating tablet formulation of the antihistamine fexofenadine, for the treatment of allergic rhinitis.
- **Q3 2024: AstraZeneca launches new combination antihistamine and corticosteroid nasal spray in the UK** AstraZeneca introduced a new prescription nasal spray combining an antihistamine and corticosteroid for the treatment of moderate to severe allergic rhinitis in the United Kingdom.
- **Q2 2025: Arcutis Biotherapeutics raises $150 million in IPO to advance topical antihistamine pipeline** Arcutis Biotherapeutics completed its initial public offering, raising $150 million to fund the development and commercialization of its pipeline of topical antihistamine therapies for dermatological allergies.
- **Q1 2025: Merck & Co. announces global supply agreement with Walgreens for OTC antihistamine Zyrtec** Merck & Co. entered into a multi-year global supply agreement with Walgreens to distribute its over-the-counter antihistamine Zyrtec across Walgreens’ international retail network.
- **Q2 2024: UCB receives FDA approval for expanded use of Xyzal in children aged 2-5 years** UCB announced that the FDA approved the expanded use of Xyzal (levocetirizine dihydrochloride) for the treatment of allergic rhinitis in children aged 2 to 5 years, broadening the drug’s pediatric indications.

## **Antihistamine Drugs Market Segmentation**

### **Antihistamine Drugs Type Outlook**

- Sedating
- Non-Sedating

### **Antihistamine Drugs Route of Administration Outlook**

- Oral Route
- Parenteral Route
- Rectal Route

### **Antihistamine Drugs Indication Outlook**

- Allergy
- Urticaria
- Dermatitis

### **Antihistamine Drugs End User Outlook**

- Hospitals
- Clinics
- Pharmaceutical Companies

### **Antihistamine Drugs Regional Outlook**

## Market Drivers

### Rising Healthcare Expenditure

다양한 지역의 의료 지출 증가는 항히스타민제 시장에 긍정적인 영향을 미칠 가능성이 높습니다. 개인이 건강과 웰니스에 더 많은 자원을 할당함에 따라 항히스타민제를 포함한 효과적인 알레르기 치료법에 대한 수요가 증가할 것으로 예상됩니다.
 
데이터에 따르면 많은 국가에서 더 나은 의료 인프라와 약물 접근에 투자하면서 의료 지출이 꾸준히 증가하고 있습니다. 이러한 추세는 약국 및 의료 시설에서 항히스타민제의 가용성을 높여 소비자 접근성을 향상시킬 수 있습니다. 또한, 의료 시스템이 발전함에 따라 예방 치료에 대한 강조가 커지고 있으며, 이로 인해 알레르기 반응에 대한 사전 대책으로 항히스타민제의 활용이 더욱 촉진될 수 있습니다.

- 세계은행(World Bank)에 따르면, 선진국과 신흥경제 모두에서 전 세계 경상 의료 지출이 지속적으로 증가하여 알레르기 진단, 처방약, 일반 항히스타민제 치료법에 대한 접근성이 향상되었습니다.

### Growing Self-Medication Trends

자가 치료에 대한 추세는 특히 항히스타민제 시장에서 더욱 뚜렷해지고 있습니다. 처방전 없이 가벼운 알레르기 반응과 증상을 관리하기 위해 일반 항히스타민제를 선택하는 소비자가 점점 늘어나고 있습니다.
 
이러한 변화는 이러한 약물에 대한 접근성이 높아지고 그 효능에 대한 인식이 높아짐에 따라 주도될 가능성이 높습니다. 시장 데이터에 따르면 일반의약품 부문은 크게 성장할 것으로 예상되며, 추정에 따르면 향후 몇 년간 약 5%의 복합 연간 성장률을 예상하고 있습니다. 이러한 추세는 소비자에게 힘을 실어줄 뿐만 아니라 자가 관리 관행에 대한 폭넓은 수용을 반영하여 정제, 액체, 비강 스프레이 등 다양한 형태의 항히스타민제에 대한 수요를 더욱 자극할 수 있습니다.

- PubMed에 따르면, 연구에 따르면 일반 항히스타민제는 유리한 안전성 프로필과 편의성으로 인해 알레르기성 비염에 가장 자주 사용되는 자가 관리 약물 중 하나로 남아 있습니다.

### Increase in Allergic Conditions

알레르기성 비염 및 두드러기와 같은 알레르기 질환의 유병률이 증가하는 것으로 나타나 항히스타민제 시장의 확대에 기여하고 있습니다. 최근 추정에 따르면 인구의 약 30%가 어떤 형태로든 알레르기를 경험하고 있으며, 이는 효과적인 항히스타민제 치료에 대한 수요를 촉진합니다.
 
이러한 알레르기 질환의 증가는 오염, 기후 변화 등 환경적 요인의 영향을 받아 증상을 악화시킬 수 있습니다. 결과적으로 의료 서비스 제공자들은 점점 더 항히스타민제를 1차 치료제로 권장하고 있으며 이에 따라 시장 성장이 강화되고 있습니다. 더욱이, 어린이와 성인 모두에게 알레르기 발생률이 증가하는 것은 항히스타민제에 대한 지속적인 수요가 있음을 시사하며, 이는 향후 몇 년간 견고한 시장 궤도를 나타냅니다.

- IHME에 따르면, 알레르기 질환은 전세계 비치명적 질병 부담에 계속해서 상당한 기여를 하고 있으며, 전 세계적으로 증가하는 의료 활용도와 항히스타민제 약물에 대한 지속적인 수요를 뒷받침하고 있습니다.

### Advancements in Drug Formulations

약물 제제의 혁신은 항히스타민제 시장을 형성하는 데 중요한 역할을 하고 있습니다. 제약회사들은 효능을 향상시키고 부작용을 감소시키는 새로운 항히스타민제 제품 개발에 점점 더 집중하고 있습니다. 예를 들어, 2세대 항히스타민제가 도입되면서 진정 효과가 덜하고 알레르기 증상 관리에 더 효과적인 약물이 개발되었습니다.
 
시장 분석에 따르면 환자와 의료 서비스 제공자가 삶의 질을 향상시키는 옵션을 모색함에 따라 이러한 발전은 새로운 제제의 시장 점유율을 크게 높일 수 있는 것으로 나타났습니다. 또한, 항히스타민제를 다른 치료제와 통합하는 병용 요법의 개발은 더 넓은 범위의 알레르기 질환에 대응하여 시장을 더욱 확대할 수 있습니다.

- PubMed에 따르면, 2세대 항히스타민제는 효과적인 증상 조절을 유지하면서 진정 효과가 현저히 낮아 향상된 안전성 프로필을 보여주어 더 많은 의사와 환자의 채택을 장려하고 있습니다.

### Increased Focus on Preventive Healthcare

예방 건강 관리에 대한 강조가 증가함에 따라 항히스타민제 시장에 주목할만한 방식으로 영향을 미치고 있습니다. 알레르기가 더 심각한 상태로 확대되기 전에 관리하는 것이 중요하다는 인식이 높아짐에 따라 소비자는 항히스타민제 치료를 적극적으로 찾을 가능성이 높습니다.
 
예방을 향한 이러한 변화는 알레르기 관리에 대한 조기 개입을 옹호하는 의료 전문가들에 의해 뒷받침됩니다. 시장 동향에 따르면 개인은 증상이 일상 생활에 영향을 미치기 전에 증상을 완화하는 것을 목표로 하기 때문에 이러한 사전 예방적 접근 방식은 항히스타민제 소비 증가로 이어질 수 있습니다. 또한 대중에게 알레르기 관리에 대해 알리는 것을 목표로 하는 교육 캠페인을 통해 항히스타민제를 예방 건강 관리 전략의 필수 요소로 활용하는 가시성과 수용성을 더욱 높일 수 있습니다.

- 세계은행(World Bank)에 따르면 예방 의료 프로그램에 대한 투자 증가는 조기 질병 관리 계획을 강화하고 적극적인 알레르기 진단과 항히스타민제 사용 확대를 장려하고 있습니다.

## Future Outlook

The Antihistamine Drugs Market size is projected to reach USD 0.4214 Billion by 2035, growing at a CAGR of 8.6%

**New opportunities:**

- Development of personalized antihistamine therapies for targeted patient demographics. Expansion into emerging markets with tailored marketing strategies. Investment in [digital healthcare](https://www.marketresearchfuture.com/reports/digital-healthcare-market-7636) platforms for allergy management solutions.

By 2035, the Antihistamine Drugs Market is expected to achieve substantial growth and innovation.

## Segment Insights

### 유형별: 진정(가장 큼) 대 비진정(가장 빠르게 성장)

항히스타민제 시장에서 이 부문은 주로 진정성 항히스타민제로 구성되어 있으며, 알레르기 증상과 수면 장애 치료에 있어 오랫동안 존재하고 효과가 있어 61%의 상당한 점유율을 차지합니다. 비진정성 항히스타민제는 시장 점유율은 작지만 졸음을 유발하지 않는 약물에 대한 소비자 선호도가 바뀌면서 주목을 받고 있습니다. 이러한 추세는 특히 젊은 층과 주간 알레르기 완화를 원하는 사람들 사이에서 비진정제 옵션의 이점에 대한 인식이 높아지고 있음을 반영합니다.

Johnson & Johnson은 확립된 알레르기 관리 제품을 통해 소비자 의료 포트폴리오를 지속적으로 확장하고, 소매 약국 네트워크 전반에 걸쳐 항히스타민제 치료법의 광범위한 가용성을 지원하고, 알레르기 약물에 대한 환자 접근성을 강화합니다.

### 투여 경로별: 경구 경로(최대) 대 비경구 경로(가장 빠르게 성장)

항히스타민제 시장에서 경구 경로는 편의성과 환자 선호도로 인해 시장 점유율 78%를 차지하는 가장 큰 부문으로 남아 있습니다. 이 경로는 투여 용이성과 정제 및 액체와 같은 다양한 제제의 가용성으로 인해 선호되며 광범위한 청중이 접근할 수 있습니다. 한편, 비경구 경로는 중증 알레르기 반응에 대한 더 빠른 환자 반응과 효과에 대한 요구로 인해 빠르게 견인력을 얻고 있으며, 이는 임상 환경에서 이 경로로의 중요한 전환을 강조합니다.

화이자(Pfizer Inc.)는 광범위한 제제 개발 및 제조 역량을 통해 경구용 의약품 혁신을 지속적으로 지원하고 경구용 의약품을 알레르기 치료 시장 전반에 걸쳐 선호하는 투여 경로로 강화합니다.

### 적응증별: 알레르기(가장 큰) 대 두드러기(가장 빠르게 자라는)

항히스타민제 시장은 주로 69%의 시장 점유율을 차지하는 알레르기 부문에 의해 주도됩니다. 계절성 및 다년성 알레르기를 포함하여 알레르기 질환의 유병률이 증가함에 따라 이 부문은 시장 환경에서 좋은 위치에 있습니다. 그 뒤를 이어 두드러기 부문은 만성 자발성 두드러기 사례 증가로 인해 주목을 받고 있으며, 이는 소비자 수요와 치료 선호도의 역동적인 변화에 기여하고 있습니다.

알레르기(우세) 대 두드러기(신생)

알레르기 부문은 광범위한 알레르기 반응과 피부 상태를 다루면서 여전히 시장 점유율을 지배하고 있습니다. 이는 꽃가루 알레르기, 음식 알레르기, 알레르기성 결막염과 같은 질환에 대한 치료법을 포함하며 폭넓은 소비자층의 관심을 끌고 있습니다. 반면, 두드러기 부문은 주로 만성 두드러기에 대한 인식 제고 및 진단 개선에 힘입어 빠른 성장 잠재력을 지닌 신흥 분야로 주목받고 있습니다. 이러한 역학은 변화하는 환자 요구와 효과적인 치료 옵션의 중요성에 대한 인식 증가를 반영하여 신제품 개발 및 시장 전략을 위한 기회를 창출합니다.

### 최종 사용자별: 병원(최대) 대 진료소(가장 빠르게 성장)

항히스타민제 시장에서 병원은 알레르기 반응 및 호흡기 문제에 대한 포괄적인 치료 계획으로 인해 상당한 56%의 점유율을 차지하는 가장 큰 최종 사용자를 나타냅니다. 클리닉은 절대적인 규모는 작지만 알레르기 환자와 경증에서 중등도의 알레르기 반응이 있는 환자에게 접근 가능한 진료를 점점 더 많이 제공하여 시장 역학에 크게 기여하면서 급속한 성장을 경험하고 있습니다.

병원(주요) vs. 진료소(신흥)

병원은 전신 치료를 통해 중증 알레르기 질환을 앓고 있는 많은 환자를 관리할 수 있는 역량을 갖추고 있어 시장 점유율에서 지배적인 최종 사용자입니다. 대규모 조달을 통해 일반의약품과 처방약을 포함한 다양한 항히스타민제 제품에 대한 꾸준한 수요를 보장합니다. 대조적으로, 클리닉은 알레르기에 대한 즉각적인 치료를 원하는 개인의 수가 증가함에 따라 이 시장에서 핵심 플레이어로 떠오르고 있습니다. 알레르기 질환의 확산이 증가함에 따라 진료소에서는 서비스 제공을 확대하고 있으며, 이로 인해 항히스타민제에 대한 수요가 증가하여 지역 의료 솔루션의 필수 구성 요소가 되었습니다.

## Regional Market Share Analysis

### 북미: 항히스타민제 시장의 선두주자

북미는 항히스타민제 시장 규모에서 선두를 달리고 있으며 2024년 전 세계 수익의 58.82% 이상을 차지했습니다. 이러한 성장은 알레르기 유병률 증가, 의료비 지출 증가, 연구 개발에 대한 집중에 의해 주도됩니다. FDA와 같은 기관의 규제 지원도 시장 확장을 촉진하여 항히스타민제 제품의 안전성과 효능을 보장했습니다.

- CDC에 따르면 미국 성인 4명 중 약 1명이 계절성 알레르기를 경험하고 있으며, 이로 인해 항히스타민제에 대한 지속적인 수요가 강화되고 북미 전역에 걸쳐 알레르기 관리 서비스가 확대되고 있습니다.

미국이 시장을 주도하고 캐나다가 그 뒤를 따르고 있으며 Johnson & Johnson, Pfizer, Merck & Co.와 같은 주요 업체가 시장을 지배하고 있습니다. 경쟁 환경은 지속적인 혁신과 새로운 제제의 도입이 특징입니다. 확립된 제약 회사의 존재는 다양한 의료 환경에서 항히스타민제의 강력한 공급망과 접근성을 보장합니다.

- GE HealthCare는 알레르기 진단과 환자 치료 인프라를 강화하는 고급 진단 기술과 의료 혁신을 지원하는 연구 개발에 연간 약 10억 달러를 투자합니다.

### 유럽: 수요 증가와 혁신

유럽 ​​항히스타민제 시장 규모는 2024년 5억 5천만 달러로 29.41%의 점유율로 두 번째로 큰 지역 시장이 되었습니다. 알레르기 질환 증가, 치료 옵션에 대한 인식 제고, 지원 규제 체계 등의 요인이 이러한 성장을 주도하고 있습니다. 유럽의약청(EMA)은 항히스타민제의 안전성과 효능을 보장하고 해당 분야의 혁신을 촉진하는 데 중요한 역할을 합니다. 독일과 프랑스는 이 지역의 선두 국가이며 Bayer AG 및 Sanofi와 같은 주요 기업이 강력한 존재감을 갖고 있습니다. 경쟁 환경은 새로운 항히스타민 제제 개발에 초점을 맞춘 기존 브랜드와 신흥 회사가 혼합되어 있다는 점에서 두드러집니다. 시장은 또한 자가 치료의 증가 추세에 영향을 받아 일반 항히스타민제의 판매가 증가했습니다.

### 아시아 태평양: 신흥 시장 잠재력

아시아 태평양 지역은 항히스타민제 시장에서 중요한 역할을 담당하며 전 세계 점유율의 약 20%를 차지하며 빠르게 성장하고 있습니다. 증가하는 오염 수준, 알레르기 질환의 증가, 효과적인 치료 옵션을 찾는 인구 증가로 인해 성장이 촉진됩니다. 인도와 중국과 같은 국가의 규제 기관도 항히스타민제의 개발 및 승인을 지원하기 위한 프레임워크를 강화하고 있습니다.

중국과 일본은 이 지역의 주요 시장이며, 점점 더 많은 현지 기업과 국제 기업이 이 분야에 진출하고 있습니다. GlaxoSmithKline 및 Novartis와 같은 주요 업체는 증가하는 수요에 부응하기 위해 제품 라인을 확장하고 있습니다. 보다 광범위한 인구를 위한 항히스타민제의 경제성과 접근성에 초점을 맞추면서 경쟁 환경이 진화하고 있습니다.

### 중동 및 아프리카: 아직 개척되지 않은 시장 기회

중동 및 아프리카 지역은 항히스타민제 시장에서 점차적으로 부상하고 있으며 전 세계 점유율의 약 5%를 차지하고 있습니다. 이러한 성장은 알레르기에 대한 인식 증가와 효과적인 치료의 필요성에 의해 주도됩니다. 규제 기관은 시장 확장에 중요한 항히스타민제의 안전성과 효능을 보장하기 위한 프레임워크를 구축하기 시작했습니다.

남아프리카공화국, UAE 등의 국가가 시장을 주도하고 있으며 현지 및 국제 제약회사의 입지가 점점 커지고 있습니다. 경쟁 환경은 경제성과 접근성에 초점을 맞춘 기존 브랜드와 신규 진입자가 혼합되어 있다는 특징이 있습니다. 이 지역은 특히 항히스타민제에 대한 인식과 접근성이 여전히 발전하고 있는 농촌 지역에서 아직 개발되지 않은 성장 기회를 제공합니다.

## Competitive Benchmarking

The Antihistamine Drugs Market is characterized by a dynamic competitive landscape, driven by increasing consumer demand for allergy relief and the ongoing development of innovative formulations. Key players such as Johnson & Johnson (US), Pfizer Inc. (US), and Sanofi (FR) are strategically positioned to leverage their extensive research capabilities and established market presence.
 
Johnson & Johnson (US) focuses on expanding its product portfolio through innovation, while Pfizer Inc. (US) emphasizes strategic partnerships to enhance its distribution channels. Sanofi (FR) is actively pursuing regional expansion, particularly in emerging markets, which collectively shapes a competitive environment that is both collaborative and competitive. The market structure appears moderately fragmented, with several players vying for market share.
 
Companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. This trend is indicative of a broader strategy among key players to adapt to regional market demands while maintaining competitive pricing. The collective influence of these major companies fosters a competitive atmosphere that encourages innovation and responsiveness to consumer needs. In August 2025, Pfizer Inc. (US) announced a strategic partnership with a leading biotechnology firm to develop next-generation antihistamines that target specific allergic responses.
 
This collaboration is significant as it not only enhances Pfizer's research capabilities but also positions the company to lead in [personalized medicine](https://www.marketresearchfuture.com/reports/personalized-medicine-market-2937) within the antihistamine segment. Such advancements may redefine treatment protocols and improve patient outcomes, thereby strengthening Pfizer's market position. In September 2025, Sanofi (FR) launched a new digital platform aimed at educating consumers about allergy management and the benefits of its antihistamine products.
 
This initiative reflects a growing trend towards digital transformation in the pharmaceutical sector, where companies are leveraging technology to engage with consumers more effectively. By enhancing customer education and support, Sanofi is likely to foster brand loyalty and drive sales in a competitive market. In July 2025, Johnson & Johnson (US) expanded its manufacturing capabilities in Asia, aiming to meet the rising demand for antihistamines in the region. This strategic move not only enhances supply chain reliability but also positions the company to respond swiftly to market fluctuations.
 
The expansion underscores the importance of regional manufacturing in maintaining competitive advantage and ensuring product availability in key markets. As of October 2025, current trends in the Antihistamine Drugs Market indicate a shift towards digitalization, sustainability, and the integration of artificial intelligence in drug development. Strategic alliances are increasingly shaping the competitive landscape, allowing companies to pool resources and expertise.
 
Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability, as companies strive to meet the complex needs of consumers in a rapidly changing market.

## Recent News & Developments

- **Q2 2024: FDA Approves First Generic Version of Xyzal (levocetirizine dihydrochloride) Oral Solution** The FDA approved the first generic version of Xyzal (levocetirizine dihydrochloride) oral solution for the treatment of indoor and outdoor allergies, expanding access to a widely used second-generation antihistamine.
- **Q1 2024: Sanofi launches Allegra-D 24 Hour Allergy & Congestion in new extended-release formulation in the U.S.** Sanofi announced the launch of a new extended-release formulation of Allegra-D 24 Hour, providing all-day relief for allergy and nasal congestion symptoms, further strengthening its OTC antihistamine portfolio.
- **Q2 2024: GSK receives European Commission approval for over-the-counter sale of Clarinex (desloratadine) in select EU countries** GSK announced that the European Commission has approved the switch of Clarinex (desloratadine) from prescription to over-the-counter status in several European Union countries, increasing consumer access to the antihistamine.
- **Q3 2024: Pfizer completes acquisition of allergy drugmaker Allermi for $1.2 billion** Pfizer finalized its acquisition of Allermi, a specialty pharmaceutical company focused on innovative antihistamine nasal sprays, expanding Pfizer’s [allergy treatment](https://www.marketresearchfuture.com/reports/allergy-treatment-market-11156) portfolio.
- **Q2 2024: Bayer opens new manufacturing facility for Claritin production in Germany** Bayer inaugurated a new state-of-the-art manufacturing facility in Leverkusen, Germany, dedicated to increasing production capacity for its leading antihistamine brand, Claritin.
- **Q1 2025: Novartis announces partnership with Alnylam to develop next-generation antihistamine therapies** Novartis and Alnylam Pharmaceuticals entered a strategic partnership to co-develop RNAi-based antihistamine drugs targeting severe allergic conditions, aiming to advance novel treatment options.
- **Q2 2025: Johnson & Johnson acquires rights to new pediatric antihistamine syrup from BioPharmX** Johnson & Johnson acquired exclusive global rights to a novel pediatric antihistamine syrup developed by BioPharmX, expanding its children’s allergy medication offerings.
- **Q1 2024: Takeda receives Japanese regulatory approval for Telfast ODT (orally disintegrating tablet) for allergic rhinitis** Takeda announced that Japan’s Ministry of Health, Labour and Welfare approved Telfast ODT, an orally disintegrating tablet formulation of the antihistamine fexofenadine, for the treatment of allergic rhinitis.
- **Q3 2024: AstraZeneca launches new combination antihistamine and corticosteroid nasal spray in the UK** AstraZeneca introduced a new prescription nasal spray combining an antihistamine and corticosteroid for the treatment of moderate to severe allergic rhinitis in the United Kingdom.
- **Q2 2025: Arcutis Biotherapeutics raises $150 million in IPO to advance topical antihistamine pipeline** Arcutis Biotherapeutics completed its initial public offering, raising $150 million to fund the development and commercialization of its pipeline of topical antihistamine therapies for dermatological allergies.
- **Q1 2025: Merck & Co. announces global supply agreement with Walgreens for OTC antihistamine Zyrtec** Merck & Co. entered into a multi-year global supply agreement with Walgreens to distribute its over-the-counter antihistamine Zyrtec across Walgreens’ international retail network.
- **Q2 2024: UCB receives FDA approval for expanded use of Xyzal in children aged 2-5 years** UCB announced that the FDA approved the expanded use of Xyzal (levocetirizine dihydrochloride) for the treatment of allergic rhinitis in children aged 2 to 5 years, broadening the drug’s pediatric indications.

## Report Scope

| MARKET SIZE 2024 | 0.17(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 0.1846(USD Billion) |
| MARKET SIZE 2035 | 0.4214(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.6% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Johnson & Johnson (US), Pfizer Inc. (US), Bayer AG (DE), Sanofi (FR), GlaxoSmithKline (GB), Novartis AG (CH), Merck & Co., Inc. (US), AstraZeneca (GB), Teva Pharmaceutical Industries Ltd. (IL) |
| Segments Covered | Type, Route of Administration, Indication, End User, Region |
| Key Market Opportunities | Emerging consumer preferences for non-drowsy formulations drive innovation in the Antihistamine Drugs Market. |
| Key Market Dynamics | Rising consumer demand for non-drowsy formulations drives innovation and competition in the antihistamine drugs market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation of the Antihistamine Drugs Market by 2035?**
A: The projected market valuation for the Antihistamine Drugs Market is 0.4214 USD Billion by 2035.

**Q: What was the market valuation of the Antihistamine Drugs Market in 2024?**
A: The overall market valuation of the Antihistamine Drugs Market was 0.17 USD Billion in 2024.

**Q: What is the expected CAGR for the Antihistamine Drugs Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the Antihistamine Drugs Market during the forecast period 2025 - 2035 is 8.6%.

**Q: Which companies are considered key players in the Antihistamine Drugs Market?**
A: Key players in the Antihistamine Drugs Market include Johnson & Johnson, Pfizer Inc., Bayer AG, Sanofi, GlaxoSmithKline, Novartis AG, Merck & Co., Inc., AstraZeneca, and Teva Pharmaceutical Industries Ltd.

**Q: What are the segment valuations for sedating and non-sedating antihistamines?**
A: In 2024, sedating antihistamines were valued at 0.07 USD Billion, while non-sedating antihistamines were valued at 0.1 USD Billion.

**Q: How do the oral, parenteral, and rectal routes of administration compare in terms of market valuation?**
A: In 2024, the oral route was valued at 0.085 USD Billion, the parenteral route at 0.045 USD Billion, and the rectal route at 0.04 USD Billion.

**Q: What indications are driving the Antihistamine Drugs Market?**
A: The market is driven by indications such as allergy, urticaria, and dermatitis, with allergy valued at 0.085 USD Billion in 2024.

**Q: What are the end-user segments for the Antihistamine Drugs Market?**
A: End-user segments include hospitals, clinics, and pharmaceutical companies, with hospitals valued at 0.06 USD Billion in 2024.

**Q: What is the projected growth trend for the Antihistamine Drugs Market from 2025 to 2035?**
A: The Antihistamine Drugs Market is expected to experience growth, reaching a valuation of 0.4214 USD Billion by 2035.

**Q: How does the market valuation for clinics compare to that of hospitals in 2024?**
A: In 2024, clinics were valued at 0.04 USD Billion, which is lower than the hospital segment valued at 0.06 USD Billion.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/antihistamine-drugs-market-4266*